A pharmacokinetics study to assess the oral administration of CB7630 (abiraterone acetate) capsule formulation and tablet formulation in patients with prostate cancer.

Trial Profile

A pharmacokinetics study to assess the oral administration of CB7630 (abiraterone acetate) capsule formulation and tablet formulation in patients with prostate cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2012

At a glance

  • Drugs Abiraterone acetate (Primary) ; Dexamethasone; Prednisolone; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Aug 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov record
    • 13 Aug 2012 Trial phase changed from I to II as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top